Pliant Therapeutics, Inc. (PLRX) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Pliant Therapeutics, Inc. (PLRX) Bundle
Explore the financial prospects of Pliant Therapeutics, Inc. (PLRX) with our user-friendly DCF Calculator! Enter your assumptions for growth, margins, and expenses to calculate the intrinsic value of Pliant Therapeutics, Inc. (PLRX) and enhance your investment approach.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 57.1 | 41.8 | 7.6 | 9.7 | 1.6 | .9 | .5 | .3 | .2 | .1 |
Revenue Growth, % | 0 | -26.7 | -81.89 | 27.91 | -83.69 | -41.09 | -41.09 | -41.09 | -41.09 | -41.09 |
EBITDA | -.1 | -40.3 | -95.7 | -118.8 | -158.2 | -.7 | -.4 | -.3 | -.2 | -.1 |
EBITDA, % | -0.20683 | -96.46 | -1264.24 | -1227.15 | -10014.43 | -79.33 | -79.33 | -79.33 | -79.33 | -79.33 |
Depreciation | 1.1 | 1.3 | 3.2 | 3.7 | 1.8 | .3 | .2 | .1 | .1 | .0 |
Depreciation, % | 1.95 | 3.13 | 42.31 | 38.01 | 116.52 | 37.08 | 37.08 | 37.08 | 37.08 | 37.08 |
EBIT | -1.2 | -41.6 | -98.9 | -122.5 | -160.1 | -.7 | -.4 | -.3 | -.2 | -.1 |
EBIT, % | -2.16 | -99.59 | -1306.55 | -1265.15 | -10130.95 | -80.35 | -80.35 | -80.35 | -80.35 | -80.35 |
Total Cash | 102.8 | 276.9 | 200.6 | 331.2 | 494.2 | .9 | .5 | .3 | .2 | .1 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | 7.4 | 9.4 | 2.0 | 2.0 | 3.0 | .3 | .2 | .1 | .1 | .0 |
Account Receivables, % | 12.94 | 22.39 | 26.39 | 20.47 | 189.68 | 36.44 | 36.44 | 36.44 | 36.44 | 36.44 |
Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Inventories, % | 0 | 0 | 0.00001320655 | 0.000010325245 | 0 | 0.000004706359 | 0.000004706359 | 0.000004706359 | 0.000004706359 | 0.000004706359 |
Accounts Payable | 1.3 | 2.0 | 3.0 | 1.6 | 4.5 | .3 | .2 | .1 | .1 | .0 |
Accounts Payable, % | 2.19 | 4.84 | 39.24 | 16.31 | 286.77 | 32.52 | 32.52 | 32.52 | 32.52 | 32.52 |
Capital Expenditure | -1.0 | -1.5 | -2.0 | -1.8 | -.9 | -.2 | -.1 | -.1 | .0 | .0 |
Capital Expenditure, % | -1.69 | -3.66 | -25.79 | -18.17 | -58.29 | -21.52 | -21.52 | -21.52 | -21.52 | -21.52 |
Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITAT | .4 | -39.9 | -89.9 | -120.7 | -160.1 | -.6 | -.3 | -.2 | -.1 | -.1 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -5.6 | -41.3 | -80.3 | -120.2 | -157.2 | -2.0 | -.2 | -.1 | -.1 | .0 |
WACC, % | 9.45 | 9.6 | 9.59 | 9.6 | 9.6 | 9.57 | 9.57 | 9.57 | 9.57 | 9.57 |
PV UFCF | ||||||||||
SUM PV UFCF | -2.2 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 0 | |||||||||
Terminal Value | -1 | |||||||||
Present Terminal Value | 0 | |||||||||
Enterprise Value | -3 | |||||||||
Net Debt | -52 | |||||||||
Equity Value | 49 | |||||||||
Diluted Shares Outstanding, MM | 59 | |||||||||
Equity Value Per Share | 0.84 |
What You Will Receive
- Comprehensive Financial Model: Pliant Therapeutics’ actual data facilitates accurate DCF valuation.
- Complete Forecasting Control: Modify revenue growth, profit margins, WACC, and other essential factors.
- Real-Time Calculations: Automatic updates provide immediate feedback as adjustments are made.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation analysis.
- Flexible and Reusable: Designed for adaptability, enabling repeated use for in-depth forecasts.
Key Features
- Comprehensive PLRX Data: Pre-loaded with Pliant Therapeutics' historical financial performance and future growth forecasts.
- Customizable Financial Inputs: Modify key metrics such as revenue growth, profit margins, WACC, tax rates, and capital expenditures.
- Interactive Valuation Model: Automatically recalculates Net Present Value (NPV) and intrinsic value based on your customized inputs.
- Scenario Analysis: Develop various forecast scenarios to evaluate different valuation possibilities.
- User-Centric Interface: Intuitive design tailored for both industry professionals and newcomers.
How It Works
- Step 1: Download the prebuilt Excel template featuring Pliant Therapeutics, Inc. (PLRX) data.
- Step 2: Navigate through the pre-filled sheets to grasp the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly see the recalculated results, including Pliant Therapeutics, Inc. (PLRX)'s intrinsic value.
- Step 5: Make well-informed investment decisions or create reports based on the outputs.
Why Choose This Calculator for Pliant Therapeutics, Inc. (PLRX)?
- User-Friendly Interface: Perfectly crafted for both novices and seasoned professionals.
- Customizable Inputs: Easily adjust parameters to suit your financial analysis needs.
- Real-Time Valuation: Observe immediate updates to Pliant Therapeutics’ valuation as you tweak the inputs.
- Preloaded Data: Comes with Pliant Therapeutics’ actual financial information for swift evaluations.
- Relied Upon by Experts: A go-to tool for investors and analysts aiming for informed decision-making.
Who Should Use This Product?
- Pharmaceutical Students: Understand drug development processes and apply them using real-world case studies.
- Researchers: Integrate advanced therapeutic models into academic projects or studies.
- Investors: Evaluate your investment strategies and assess valuation outcomes for Pliant Therapeutics, Inc. (PLRX).
- Market Analysts: Enhance your analysis with a customizable financial model tailored for biotech firms.
- Healthcare Entrepreneurs: Discover insights into how public biotech companies like Pliant Therapeutics are evaluated.
What the Template Contains
- Pre-Filled Data: Includes Pliant Therapeutics' historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze Pliant Therapeutics' profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.